SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Lopez Sendon J.)
 

Sökning: WFRF:(Lopez Sendon J.) > Non-adherence to iv...

Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT

Bohm, M. (författare)
Lloyd, S. M. (författare)
Ford, I. (författare)
visa fler...
Borer, J. S. (författare)
Ewen, S. (författare)
Laufs, U. (författare)
Mahfoud, F. (författare)
Lopez-Sendon, J. (författare)
Ponikowski, P. (författare)
Tavazzi, L. (författare)
Swedberg, Karl, 1944 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
Komajda, M. (författare)
visa färre...
 (creator_code:org_t)
2016-03-08
2016
Engelska.
Ingår i: European Journal of Heart Failure. - : Wiley. - 1388-9842 .- 1879-0844. ; 18:6, s. 672-683
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • AimsIn heart failure, non-adherence increases events; in turn, the effect of hospitalization on adherence is incompletely understood. We explored the relationship of non-adherence to outcomes, hospitalizations with non-adherence, and the influence of non-adherence on treatment effects of heart rate lowering with ivabradine. Methods and resultsIn the randomized, controlled Systolic Heart failure treatment with the If-inhibitor ivabradine Trial (SHIFT), we studied the effect of non-adherence (n = 1287) compared with adherence (n=5204) on cardiovascular outcomes. After adjustment, non-adherence was associated with the primary composite endpoint of cardiovascular death and heart failure hospitalization (hazard ratio 3.47, 95% confidence interval 2.91-4.13, P < 0.0001). No interaction with the treatment groups of placebo or ivabradine (P for interaction 0.54) occurred. Similar results for cardiovascular death and heart failure hospitalization, as well as for cardiovascular hospitalization, heart failure death, and total death were observed. The effect of ivabradine was maintained in patients being adherent or becoming non-adherent during the trial (P for interaction=0.54). Patients with a previous hospitalization were more likely to become non-adherent thereafter. ConclusionsNon-adherence identifies a group at particularly high cardiovascular event risk independent of treatment allocation. Non-adherent patients in the ivabradine group maintain a treatment benefit. Patients with previous hospitalizations are more likely to become non-adherent and represent a group of particularly high-risk patients in whom special attention to stimulate adherence may be valuable.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

Heart failure
SHIFT
Heart rate
Adherence
Cardiovascular hospitalizations
evidence-based pharmacotherapy
medication adherence
follow-up
cardiovascular outcomes
myocardial-infarction
drug adherence
older
patients
double-blind
mortality
association
Cardiovascular System & Cardiology

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy